Abstract P1-18-05: Subcutaneous trastuzumab and hyaluronidase-oysk with intravenous pertuzumab and docetaxel in HER2-positive advanced breast cancer: Final analysis of the phase IIIb, multicenter, open-label, single-arm MetaPHER study

Mapping Intimacies ◽

10.1158/1538-7445.sabcs19-p1-18-05 ◽

2020 ◽

Author(s):

Sherko Kümmel ◽

Carlo A Tondini ◽

Jacinta Abraham ◽

Zbigniew Nowecki ◽

Bartosz Itrych ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Final Analysis ◽

Advanced Breast ◽

Her2 Positive ◽

Open Label ◽

Phase Iiib

Download Full-text

Abstract OT3-01-13: MetaPHER: A phase IIIb multicenter, open-label, single-arm safety study of subcutaneous trastuzumab, in combination with pertuzumab and docetaxel in patients with HER2-positive advanced breast cancer

10.1158/1538-7445.sabcs15-ot3-01-13 ◽

2016 ◽

Author(s):

S Kümmel ◽

A Crepelle-Fléchais ◽

M Schlegel ◽

C Hillenbach ◽

A Swat ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Her2 Positive ◽

Open Label ◽

Safety Study ◽

Phase Iiib

Download Full-text

Abstract P4-21-42: MetaPHER phase IIIb multicenter, open-label, single-arm safety study of subcutaneous trastuzumab in combination with pertuzumab and docetaxel in patients with HER2-positive advanced breast cancer: First results

10.1158/1538-7445.sabcs16-p4-21-42 ◽

2017 ◽

Cited By ~ 2

Author(s):

S Kümmel ◽

J Abraham ◽

M Martin ◽

A Crepelle-Fléchais ◽

A Swat ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Her2 Positive ◽

Open Label ◽

Safety Study ◽

Phase Iiib ◽

First Results

Download Full-text

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(14)70178-0 ◽

2014 ◽

Vol 15 (7) ◽

pp. 689-699 ◽

Cited By ~ 350

Author(s):

Ian E Krop ◽

Sung-Bae Kim ◽

Antonio González-Martín ◽

Patricia M LoRusso ◽

Jean-Marc Ferrero ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Versus Treatment

Download Full-text

Abstract OT1-1-02: A single-arm phase IIIb study of pertuzumab and trastuzumab with a taxane as first-line therapy for patients with HER2-positive advanced breast cancer (PERUSE)

10.1158/0008-5472.sabcs12-ot1-1-02 ◽

2012 ◽

Cited By ~ 4

Author(s):

T Bachelot ◽

E Ciruelos ◽

T Peretz-Yablonski ◽

A Schneeweiss ◽

F Puglisi ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

First Line ◽

Her2 Positive ◽

First Line Therapy ◽

Line Therapy ◽

Phase Iiib

Download Full-text

223P Safety and tolerability of subcutaneous trastuzumab (H SC) self-administered at home via single-use injection device (SID) in patients (pts) with HER2-positive early breast cancer (EBC): Primary and final analysis of the open-label, phase IIIB HOMERUS study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.2334 ◽

2020 ◽

Vol 31 ◽

pp. S330

Author(s):

A.J. ten Tije ◽

S. van Steenis ◽

J. Briers ◽

E.M.P. Elsten

Keyword(s):

Breast Cancer ◽

Early Breast Cancer ◽

Final Analysis ◽

Injection Device ◽

Her2 Positive ◽

Open Label ◽

Phase Iiib ◽

Open Label Phase ◽

Single Use ◽

At Home

Download Full-text

Faculty Opinions recommendation of Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718373656.793494835 ◽

2014 ◽

Author(s):

Ana Maria Gonzalez-Angulo

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Open Label ◽

Phase 3 ◽

Open Label Phase ◽

Versus Treatment

Download Full-text

A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-012-2399-4 ◽

2013 ◽

Vol 137 (3) ◽

pp. 755-766 ◽

Cited By ~ 33

Author(s):

Stephen R. D. Johnston ◽

Henry Gómez ◽

Salomon M. Stemmer ◽

Maria Richie ◽

Michael Durante ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

First Line ◽

Her2 Positive ◽

Open Label ◽

First Line Therapy ◽

Line Therapy ◽

Open Label Trial

Download Full-text

Pertuzumab in Combination with Trastuzumab and a Taxane for the First-Line Treatment of Patients with HER2-Positive Advanced Breast Cancer: A Single Arm Phase IIIB Study (Peruse)

Annals of Oncology ◽

10.1016/s0923-7534(20)32977-x ◽

2012 ◽

Vol 23 ◽

pp. ix142-ix143

Author(s):

D. Miles ◽

T. Peretz-Yablonski ◽

E. Ciruelos ◽

F. Puglisi ◽

A. Schneeweiss ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Advanced Breast ◽

Line Treatment ◽

First Line ◽

Her2 Positive ◽

Phase Iiib ◽

First Line Treatment

Download Full-text

Results of Two Open-Label, Multicenter Phase II Studies of Docetaxel, Platinum Salts, and Trastuzumab in HER2-Positive Advanced Breast Cancer

JNCI Journal of the National Cancer Institute ◽

10.1093/jnci/djh133 ◽

2004 ◽

Vol 96 (10) ◽

pp. 759-769 ◽

Cited By ~ 210

Author(s):

M. D. Pegram ◽

T. Pienkowski ◽

D. W. Northfelt ◽

W. Eiermann ◽

R. Patel ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Phase Ii ◽

Advanced Breast ◽

Her2 Positive ◽

Open Label ◽

Multicenter Phase ◽

Platinum Salts ◽

Phase Ii Studies

Download Full-text

Pyrotinib in Combination With Nab-paclitaxel in Patients With HER2-positive Advanced Breast Cancer: an Exploratory Study

Case Medical Research ◽

10.31525/ct1-nct03919253 ◽

2019 ◽

Author(s):

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Exploratory Study ◽

Advanced Breast ◽

Her2 Positive

Download Full-text